DBV Technologies Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin® Milk in Pediatric Cow''s Milk Allergy
(Thomson Reuters ONE) -
Press Release
Bagneux, France, June 30, 2015
DBV Technologies Announces Completion of Part A of the MILES Study Evaluating
the Safety of Viaskin(®) Milk in Pediatric Cow''s Milk Allergy
DSMB expressed no safety concerns and recommended that the study continue as
planned
Initiation of Part B expected in the second half of 2015 pending consultation
with regulatory agencies
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage, specialty biopharmaceutical company, today announced
the completion of Phase I or Part A, of the Viaskin Milk Efficacy and Safety
Phase I/II study (MILES). The Data Safety Monitoring Board (DSMB) for the study
recommended that the study continue and expressed no safety concerns after
evaluating the Part A safety data of subjects treated with a 150 micrograms,
300 micrograms and 500 micrograms doses of Viaskin Milk.
The MILES study is a two part, multi-center, double-blind, placebo-controlled,
randomized clinical trial designed to evaluate the safety and efficacy of
Viaskin® Milk in IgE-mediated cow''s milk protein allergic (CMPA) patients
ranging from two to 17 years of age. Part A evaluated the safety of three
escalating doses of Viaskin® Milk (150 micrograms,
300 micrograms and 500 micrograms) versus placebo over three weeks in 18
patients.
Pending review of the Part A data by the U.S. Food & Drug Administration (FDA)
and U.S. and Canadian approvals of the revised protocol described below, the
Company intends to initiate Part B of the trial in the second half of 2015. Part
B, or Phase II, of the MILES study is expected evaluate the efficacy and safety
of all three doses of Viaskin® Milk (150 micrograms,
300 micrograms, 500 micrograms) versus placebo for 12 months. Approximately 176
patients between two and 17 years of age are expected to be randomized in a
1:1:1:1 ratio at selected North American sites.
About the MILES Study
The MILES trial is a multi-center, double-blind, placebo-controlled, randomized
Phase I/II trial to study the safety and efficacy of Viaskin Milk in pediatric
patient populations (age two to 17) suffering from IgE-mediated cow''s milk
protein allergy, or CMPA, with elevated IgE levels related to cow''s milk
protein. The trial is being conducted in select U.S. and Canadian clinical
centers. Part A of the MILES trial has been completed. Under the proposed
amended MILES Part B protocol, up to 176 subjects are expected to be randomized
for treatment at approximately 18 sites. Eligible subjects with confirmed IgE-
mediated CMPA will perform an initial food challenge at screening with
escalating doses of cow''s milk proteins. Subjects who display objective signs or
symptoms of allergic response to an eliciting dose of 300 mg cow''s milk proteins
(approximately 9.4 mL of cow''s milk) or below will be randomized in the trial.
The primary efficacy endpoint will be the percentage of subjects who are
treatment responders after 12 months, defined as subjects who meet at least one
of the following criteria: (1) a 10-fold or greater increase in the cumulative
reactive dose, or CRD, of cow''s milk proteins at month 12 of the food challenge
as compared to baseline value in addition to reaching tolerance to at least 144
mg of cow''s milk protein (approximately 4.5 mL of milk) or (2) a CRD of cow''s
milk protein greater than or equal to 1,444 mg (approximately 45 mL of milk) at
month 12 of the food challenge. Secondary efficacy endpoints include, among
others, the percentage of subjects who are treatment responders at month 24, the
mean and median CRD of cow''s milk proteins at months 12 and 24 as well as the
change in CRD from baseline, the change from baseline in the severity of
symptoms elicited during the food challenge from baseline to months 12 and 24,
and the change from baseline in quality of life assessments at months 12 and 24.
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the
treatment of allergies - a major public health issue that has been increasing in
prevalence. DBV Technologies, incorporated in France in 2002, has developed a
proprietary, patented technology for administering an allergen to intact skin
while avoiding transfer to the blood, and thus lowering the risk of a systemic,
allergic reaction in the event of accidental exposure. DBV Technologies is
focusing on food allergies, including milk and peanut, for which there are
currently no effective treatments. DBV Technologies has designed two products
candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program
for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy
designation from the U.S. Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV,
ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American
Depositary Shares (each representing one-half of one ordinary share) (Ticker:
DBVT). For more information on DBV Technologies, please visit our website:
www.dbv-technologies.com
Forward Looking Statements
This press release contains forward-looking statements, including statements
about the potential safety and efficacy of Epicutenaous Immunotherapy (EPIT®)
via Viaskin® Milk and DBV''s anticipated clinical development of Viaskin Milk and
other product candidates. These forward-looking statements are not promises or
guarantees and involve substantial risks and uncertainties. The Company''s
product candidates have not been approved for sale in any jurisdiction. Among
the factors that could cause actual results to differ materially from those
described or projected herein are uncertainties associated generally with
research and development, clinical trials and related regulatory reviews and
approvals, the risk that historical preclinical results may not be predictive of
future clinical trial results, and the risk that historical clinical trial
results may not be predictive of future trial results. A further list and
description of these risks, uncertainties and other risks can be found in the
Company''s regulatory filings with the French Autorité des Marchés Financiers,
the Company''s Securities and Exchange Commission filings and reports, including
in the Company''s Annual Report on Form 20-F for the year ended December
31, 2014 and future filings and reports by the Company. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. DBV Technologies undertakes
no obligation to update or revise the information contained in this Press
Release, whether as a result of new information, future events or circumstances
or otherwise.
DBV Technologies Contacts
Nathalie Donne Susanna Mesa
Director, Corporate Communication & VP Finance, US Investor Relations &
Business Development Strategy
Tél. : +33(0)1 55 42 78 72 Tél. : +1 917-346-3447
nathalie.donne(at)dbv-technologies.com susanna.mesa(at)dbv-technologies.com
DBV Technologies Media Contacts US & Europe
Marion Janic Caroline Carmagnol
Rooney & Associates Alize RP - Relation Presse
Tél. : +1-212-223-4017 Tél. : +33(0)6 64 18 99 59
mjanic(at)rooneyco.com caroline(at)alizerp.com
Milk-EN:
http://hugin.info/156437/R/1932663/695386.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#1932663]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.06.2015 - 01:30 Uhr
Sprache: Deutsch
News-ID 1369201
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Bagneux
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 308 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin® Milk in Pediatric Cow''s Milk Allergy
"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
